Ost-müük Kaleido Biosciences, Inc. - KLDO CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Kauplemistingimused
| Hinnavahe | 0.05 | ||||||||
|
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.024068% | ||||||||
|
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.001846% | ||||||||
| Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
| Min kauplemise kogus | 1 | ||||||||
| Valuuta | USD | ||||||||
| Tagatis | 20% | ||||||||
| Aktsiabörs | United States of America | ||||||||
| Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Võtmestatistika
| Eelmine sulgemine* | 0.39 |
| Avatud* | 0.4 |
| Aastane muutus* | 2.56% |
| Päeva ulatus* | 0.38 - 0.45 |
| 52 nädala ulatus | 0.00-1.92 |
| Keskmine maht (10 päeva) | 26.79K |
| Keskmine maht (3 kuud) | 306.37K |
| Turukapitalisatsioon | 8,520.00 |
| P/E suhtarv | -100.00K |
| Ringluses olevad aktsiad | 42.62M |
| Tulu | 1.10M |
| EPS | -2.16 |
| Dividendid (% kasumist) | N/A |
| Beeta | 0.47 |
| Järgmine tuluaruande kuupäev | Mar 23, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
|---|---|---|---|---|---|---|
| Apr 14, 2022 | 0.38 | 0.00 | 0.00% | 0.38 | 0.38 | 0.38 |
| Apr 13, 2022 | 0.39 | 0.00 | 0.00% | 0.39 | 0.47 | 0.38 |
| Apr 8, 2022 | 0.40 | -0.24 | -37.50% | 0.64 | 0.64 | 0.38 |
| Apr 7, 2022 | 1.46 | -0.01 | -0.68% | 1.47 | 1.55 | 1.42 |
| Apr 6, 2022 | 1.46 | -0.02 | -1.35% | 1.48 | 1.48 | 1.42 |
| Apr 5, 2022 | 1.50 | -0.09 | -5.66% | 1.59 | 1.62 | 1.48 |
| Apr 4, 2022 | 1.59 | -0.14 | -8.09% | 1.73 | 1.73 | 1.54 |
| Apr 1, 2022 | 1.68 | 0.06 | 3.70% | 1.62 | 1.70 | 1.58 |
| Mar 31, 2022 | 1.60 | -0.08 | -4.76% | 1.68 | 1.72 | 1.55 |
| Mar 30, 2022 | 1.69 | -0.14 | -7.65% | 1.83 | 1.83 | 1.69 |
| Mar 29, 2022 | 1.70 | 0.02 | 1.19% | 1.68 | 1.77 | 1.60 |
| Mar 28, 2022 | 1.60 | -0.13 | -7.51% | 1.73 | 1.73 | 1.50 |
| Mar 25, 2022 | 1.64 | -0.10 | -5.75% | 1.74 | 1.74 | 1.63 |
| Mar 24, 2022 | 1.74 | 0.00 | 0.00% | 1.74 | 1.76 | 1.68 |
| Mar 23, 2022 | 1.74 | 0.01 | 0.58% | 1.73 | 1.81 | 1.73 |
| Mar 22, 2022 | 1.75 | 0.10 | 6.06% | 1.65 | 1.75 | 1.65 |
| Mar 21, 2022 | 1.63 | -0.05 | -2.98% | 1.68 | 1.68 | 1.55 |
| Mar 18, 2022 | 1.67 | 0.14 | 9.15% | 1.53 | 1.71 | 1.53 |
| Mar 17, 2022 | 1.56 | 0.14 | 9.86% | 1.42 | 1.57 | 1.42 |
| Mar 16, 2022 | 1.42 | 0.04 | 2.90% | 1.38 | 1.42 | 1.31 |
Kaleido Biosciences, Inc. Events
| Kellaaeg (UTC) (UTC) | Riik | Sündmus |
|---|---|---|
| No events scheduled | ||
- Aastas
- Kvartalis
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Kogutulu | 1.104 | 0.975 | 0 | 0 | 0 |
| Kogu tegevuskulu | 88.771 | 79.849 | 87.24 | 60.683 | 27.03 |
| Müük/Üldine/admin kulud, kokku | 20.968 | 23.882 | 22.428 | 18.621 | 6.038 |
| Uuringud ja arendus | 67.803 | 55.967 | 64.232 | 42.062 | 20.992 |
| Tulud majandustegevusest | -87.667 | -78.874 | -87.24 | -60.683 | -27.03 |
| Intressitulud (kulu), muud tulud, neto | -2.766 | -2.553 | 0.968 | -0.805 | -0.512 |
| Muud, neto | 0.145 | -0.193 | -0.059 | -0.256 | -0.017 |
| Netotulu enne makse | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
| Netotulu pärast makse | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
| Netotulu enne erikulusid | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
| Netotulu | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
| Arvestatav tulu, v a erikulud | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
| Arvestatav tulu, koos erikuludega | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
| Jaotamisele kuuluv netotulu | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
| Keskmine jaotamisele kuuluv aktsia kohta | 41.86 | 33.4502 | 25.7033 | 29.3948 | 29.3948 |
| Jaotatav EPS, v a erakorralised kulud | -2.1569 | -2.44004 | -3.35876 | -2.10051 | -0.93755 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
| Jaotamisele kuuluv normaal-EPS | -2.1569 | -2.44004 | -3.33619 | -2.10051 | -0.93755 |
| Ootamatud kulutused (tulu) | 0 | 0.58 | |||
| Tulu | 1.104 | 0.975 |
| Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | |
|---|---|---|---|---|---|
| Kogutulu | 0.492 | 0.104 | 0.211 | 0.297 | 0.243 |
| Tulu | 0.492 | 0.104 | 0.211 | 0.297 | 0.243 |
| Kogu tegevuskulu | 20.191 | 22.517 | 23.418 | 22.645 | 19.543 |
| Müük/Üldine/admin kulud, kokku | 4.617 | 5.106 | 5.785 | 5.46 | 5.205 |
| Uuringud ja arendus | 15.574 | 17.411 | 17.633 | 17.185 | 14.338 |
| Ootamatud kulutused (tulu) | 0 | ||||
| Tulud majandustegevusest | -19.699 | -22.413 | -23.207 | -22.348 | -19.3 |
| Intressitulud (kulu), muud tulud, neto | -0.705 | -0.692 | -0.681 | -0.688 | -0.713 |
| Muud, neto | 0.132 | 0.02 | -0.001 | -0.006 | -0.003 |
| Netotulu enne makse | -20.272 | -23.085 | -23.889 | -23.042 | -20.016 |
| Netotulu pärast makse | -20.272 | -23.085 | -23.889 | -23.042 | -20.016 |
| Netotulu enne erikulusid | -20.272 | -23.085 | -23.889 | -23.042 | -20.016 |
| Netotulu | -20.272 | -23.085 | -23.889 | -23.042 | -20.016 |
| Arvestatav tulu, v a erikulud | -20.272 | -23.085 | -23.889 | -23.042 | -20.016 |
| Arvestatav tulu, koos erikuludega | -20.272 | -23.085 | -23.889 | -23.042 | -20.016 |
| Jaotamisele kuuluv netotulu | -20.272 | -23.085 | -23.889 | -23.042 | -20.016 |
| Keskmine jaotamisele kuuluv aktsia kohta | 42.5995 | 42.5776 | 42.5386 | 39.6926 | 35.9841 |
| Jaotatav EPS, v a erakorralised kulud | -0.47587 | -0.54219 | -0.56158 | -0.58051 | -0.55625 |
| Jaotamisele kuuluv normaal-EPS | -0.47587 | -0.54219 | -0.56158 | -0.58051 | -0.55625 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 |
- Aastas
- Kvartalis
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 42.311 | 48.721 | 73.279 | 76.243 | 28.551 |
| Raha ja lühiajalised investeeringud | 38.474 | 46.222 | 71.241 | 76.086 | 28.456 |
| Raha ja ekvivalendid | 38.474 | 46.222 | 71.241 | 76.086 | 28.456 |
| Laekumata arved, neto | 0.005 | 0.045 | |||
| Prepaid Expenses | 3.583 | 2.499 | 2.038 | 0.152 | 0.05 |
| Total Assets | 50.137 | 59.344 | 82.306 | 85.325 | 30.747 |
| Property/Plant/Equipment, Total - Net | 5.665 | 8.462 | 6.742 | 4.693 | 1.975 |
| Property/Plant/Equipment, Total - Gross | 11.136 | 11.955 | 9.281 | 5.914 | 2.406 |
| Accumulated Depreciation, Total | -5.471 | -3.493 | -2.539 | -1.221 | -0.431 |
| Other Long Term Assets, Total | 2.161 | 2.161 | 2.285 | 4.389 | 0.221 |
| Total Current Liabilities | 29.682 | 16.659 | 10.377 | 11.301 | 3.854 |
| Accounts Payable | 5.67 | 5.389 | 2.016 | 3.442 | 0.864 |
| Accrued Expenses | 6.686 | 7.356 | 7.086 | 7.406 | 2.615 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 16.144 | 2.634 | 0.068 | 0.091 | 0.104 |
| Other Current Liabilities, Total | 1.182 | 1.28 | 1.207 | 0.362 | 0.271 |
| Total Liabilities | 39.53 | 38.848 | 33.423 | 28.343 | 21.932 |
| Total Long Term Debt | 5.55 | 18.375 | 20.391 | 14.831 | 14.81 |
| Long Term Debt | 5.55 | 18.375 | 20.391 | 14.831 | 14.81 |
| Other Liabilities, Total | 4.298 | 3.814 | 2.655 | 2.211 | 3.268 |
| Total Equity | 10.607 | 20.496 | 48.883 | 56.982 | 8.815 |
| Preferred Stock - Non Redeemable, Net | 153.226 | 52.494 | |||
| Common Stock | 0.043 | 0.036 | 0.03 | 0.006 | 0.005 |
| Additional Paid-In Capital | 375.031 | 294.639 | 241.412 | 9.978 | 0.8 |
| Retained Earnings (Accumulated Deficit) | -364.467 | -274.179 | -192.559 | -106.228 | -44.484 |
| Total Liabilities & Shareholders’ Equity | 50.137 | 59.344 | 82.306 | 85.325 | 30.747 |
| Total Common Shares Outstanding | 42.596 | 36.0228 | 30.1278 | 29.3948 | 29.3948 |
| Redeemable Preferred Stock | 0 | 0 | |||
| Other Current Assets, Total | 0.254 |
| Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 42.311 | 58.304 | 74.603 | 95.032 | 48.721 |
| Raha ja lühiajalised investeeringud | 38.474 | 55.657 | 71.979 | 92.362 | 46.222 |
| Raha ja ekvivalendid | 38.474 | 55.657 | 71.979 | 92.362 | 46.222 |
| Prepaid Expenses | 3.583 | 2.647 | 2.624 | 2.67 | 2.499 |
| Total Assets | 50.137 | 67.804 | 84.29 | 105.026 | 59.344 |
| Property/Plant/Equipment, Total - Net | 5.665 | 7.339 | 7.526 | 7.833 | 8.462 |
| Property/Plant/Equipment, Total - Gross | 11.136 | 12.482 | 12.165 | 11.889 | 11.955 |
| Accumulated Depreciation, Total | -5.471 | -5.143 | -4.639 | -4.056 | -3.493 |
| Other Long Term Assets, Total | 2.161 | 2.161 | 2.161 | 2.161 | 2.161 |
| Total Current Liabilities | 29.682 | 19.261 | 12.269 | 12.873 | 16.659 |
| Accounts Payable | 5.67 | 3.559 | 2.695 | 2.412 | 5.389 |
| Accrued Expenses | 6.686 | 8.681 | 5.014 | 4.403 | 7.356 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 16.144 | 6.384 | 3.667 | 4.759 | 2.634 |
| Other Current Liabilities, Total | 1.182 | 0.637 | 0.893 | 1.299 | 1.28 |
| Total Liabilities | 39.53 | 38.604 | 34.024 | 33.252 | 38.848 |
| Total Long Term Debt | 5.55 | 15.132 | 17.677 | 16.433 | 18.375 |
| Long Term Debt | 5.55 | 15.132 | 17.677 | 16.433 | 18.375 |
| Other Liabilities, Total | 4.298 | 4.211 | 4.078 | 3.946 | 3.814 |
| Total Equity | 10.607 | 29.2 | 50.266 | 71.774 | 20.496 |
| Common Stock | 0.043 | 0.043 | 0.043 | 0.042 | 0.036 |
| Additional Paid-In Capital | 375.031 | 373.352 | 371.333 | 368.953 | 294.639 |
| Retained Earnings (Accumulated Deficit) | -364.467 | -344.195 | -321.11 | -297.221 | -274.179 |
| Total Liabilities & Shareholders’ Equity | 50.137 | 67.804 | 84.29 | 105.026 | 59.344 |
| Total Common Shares Outstanding | 42.596 | 42.5801 | 42.5714 | 42.4832 | 36.0228 |
| Redeemable Preferred Stock | 0 | 0 | |||
| Other Current Assets, Total | 0.254 |
- Aastas
- Kvartalis
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Netotulu/algväärtus | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
| Raha majandustegevusest | -77.094 | -61.518 | -75.796 | -46.316 | -22.495 |
| Raha majandustegevusest | 2.358 | 1.823 | 1.318 | 0.792 | 0.316 |
| Mittelikviidsed varad | 11.099 | 13.728 | 10.433 | 8.14 | 0.738 |
| Makstud intressid | 2.133 | 1.925 | 0.881 | 0.943 | 0.343 |
| Muutused tööjõus | -0.263 | 4.551 | -1.216 | 6.496 | 4.01 |
| Tulu investeeringutelt | -0.691 | -4.024 | -3.586 | -3.002 | -1.406 |
| Kapitalikulutused | -1.129 | -4.024 | -3.586 | -3.002 | -1.406 |
| Rahavood investeeringutelt | 70.037 | 40.399 | 74.642 | 98.907 | 49.736 |
| Rahavoogudesse investeerimine | -0.359 | -0.079 | -1.158 | -1.84 | 0 |
| Aktsiate emiteerimine (tagasiost), neto | 70.396 | 40.546 | 68.391 | 100.852 | 39.86 |
| Laenu väljastamine (kustutamine), neto | 0 | -0.068 | 7.409 | -0.105 | 9.876 |
| Rahaline kogumuutus | -7.748 | -25.143 | -4.74 | 49.589 | 25.835 |
| Muud rahavood investeeringutelt, kokku | 0.438 |
| Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -90.288 | -70.016 | -46.931 | -23.042 | -81.62 |
| Cash From Operating Activities | -77.094 | -59.934 | -44.057 | -23.974 | -61.518 |
| Cash From Operating Activities | 2.358 | 1.754 | 1.16 | 0.577 | 1.823 |
| Non-Cash Items | 11.099 | 9.331 | 7.146 | 4.603 | 13.728 |
| Cash Interest Paid | 2.133 | 1.601 | 1.064 | 0.526 | 1.925 |
| Changes in Working Capital | -0.263 | -1.003 | -5.432 | -6.112 | 4.551 |
| Cash From Investing Activities | -0.691 | -0.693 | -0.262 | -0.03 | -4.024 |
| Capital Expenditures | -1.129 | -0.693 | -0.262 | -0.03 | -4.024 |
| Cash From Financing Activities | 70.037 | 70.062 | 70.076 | 70.144 | 40.399 |
| Financing Cash Flow Items | -0.359 | -0.329 | -0.31 | -0.186 | -0.079 |
| Issuance (Retirement) of Stock, Net | 70.396 | 70.391 | 70.386 | 70.33 | 40.546 |
| Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | -0.068 | |
| Net Change in Cash | -7.748 | 9.435 | 25.757 | 46.14 | -25.143 |
| Other Investing Cash Flow Items, Total | 0.438 |
| Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
|---|---|---|---|---|---|---|
| Menichella (Daniel L.) | Individual Investor | 0.2996 | 127700 | 107700 | 2022-03-31 | MED |
| Duke (William E. Jr.) | Individual Investor | 0.1598 | 68115 | 68115 | 2022-03-31 | LOW |
| Korn (Jerald) | Individual Investor | 0.1215 | 51803 | 51803 | 2022-03-31 | |
| Melas-Kyriazi (Theo) | Individual Investor | 0.0782 | 33333 | 0 | 2022-03-31 | LOW |
| Quinn (Anthony G) | Individual Investor | 0.0741 | 31603 | 0 | 2022-03-31 | LOW |
| Northern Trust Global Investments | Investment Advisor | 0.0334 | 14235 | 14235 | 2022-12-31 | LOW |
| DWS Investments UK Limited | Investment Advisor | 0.0244 | 10387 | 0 | 2023-02-28 | MED |
| Amalgamated Financial Corp. | Investment Advisor | 0.0077 | 3266 | 3266 | 2022-03-31 | |
| Mackenzie Financial Corporation | Investment Advisor/Hedge Fund | 0.0027 | 1139 | -148 | 2022-09-30 | LOW |
| Westfield Capital Management Company, L.P. | Investment Advisor/Hedge Fund | 0.002 | 854 | 0 | 2021-09-30 | LOW |
| Carroll Financial Associates, Inc. | Investment Advisor | 0.0008 | 339 | 0 | 2021-12-31 |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group500K+
Kauplejad
92K+
Igakuiste aktiivsete klientide arv
$53M+
Igakuine investeerimise maht
$30M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
Kauplemise vahendustasu
0
- 1:1
Finantsvõimendus
1:1
- 20
- 100
- 500
- 1000
- 10000
Investeering
Tehingu suurus (võimendus x investeering):
Avamishind
Close
Lühike Pikk
Kaleido Biosciences, Inc. Company profile
Ettevõttest Kaleido Biosciences, Inc.
Kaleido Biosciences, Inc. on kliinilises staadiumis olev tervishoiuettevõte, mis keskendub mikroorganismi potentsiaali ärakasutamisele haiguste raviks ja inimeste tervise parandamiseks. Tema Microbiome Metabolic Therapies (MMT) on mõeldud mikrobioomi olemasolevate mikroobide funktsiooni ja jaotuse juhtimiseks, et vähendada või suurendada metaboliitide tootmist teatud bakteritele mikrobioomi kogukonnas. Ettevõte edendab ka MMT-kandidaatide laia valikut, mis võivad lahendada mitmesuguseid haigusi ja seisundeid, mille puhul on patsientidel rahuldamata vajadused. Ettevõte kasutab oma avastamis- ja arendusplatvormi MMT-de uurimiseks mikrobioomiproovides, et viia MMT-kandidaadid kiiresti kliinilistesse uuringutesse tervetel isikutel ja patsientidel. Ettevõtte KB195 on juhtiv MMT-kandidaat, mida arendatakse uureatsüklihäiretega patsientide raviks. Ettevõte viib läbi II faasi kliinilist uuringut uue ravimi taotluse (IND) alusel.
| Industry: | Biotechnology & Medical Research (NEC) |
18 Crosby Dr
BEDFORD
MASSACHUSETTS 01730-1402
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 500,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com